Developer docs
API playgroundTry for free, no card

Search company profiles

Repligen

Full company profile

uuid0000yne

Namestring
Repligen
Legal namestring
Repligen Corporation
Websiteurl
repligen.com
Company typeenum
Public
Founded yearint
1981
Descriptiontext

Repligen Corporation (NASDAQ: RGEN) is a publicly traded bioprocessing technology company founded in 1981 and headquartered in Waltham, Massachusetts. It develops and manufactures consumables, equipment, and integrated systems used by biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and advanced therapy developers for the production of biological drugs including monoclonal antibodies, viral vectors, mRNA, pDNA, and antibody-drug conjugates.

The product portfolio spans four integrated franchises: upstream filtration (XCell ATF perfusion systems for cell retention and process intensification), downstream processing (KrosFlo TFF systems, TangenX cassettes, Spectrum hollow fiber filters), chromatography (KRM systems, OPUS pre-packed columns spanning 1.2cm to 80cm diameters, AVIPure and HiPer affinity/ion exchange resins), and process analytics (PATsmart family including FlowVPX, SoloVPE, REBEL XT, and ZipChip instruments built on proprietary Variable Pathlength Spectroscopy). Supporting these are fluid management solutions (ProConnex flow paths, Metenova magnetic mixing), cell culture supplements (LONG R3 IGF-I, LONG EGF), ligands (rSPA, Protein A, NGL-Impact A), and the Real-time Process Management (RPM) platform that ties FlowVPX analytics directly into KrosFlo TFF for closed-loop concentration control. Manufacturing spans 13+ ISO-certified facilities across the US, Netherlands, Germany, Sweden, Ireland, Estonia, and Taiwan.

Repligen operates a hybrid B2B go-to-market combining direct enterprise field sales supported by field application specialists, an e-commerce storefront for standard products, and a global distributor network. Revenue is generated through capital equipment sales (TFF, chromatography, perfusion systems), recurring consumables (resins, cassettes, filters, flow paths), professional services (installation, qualification, maintenance, training), and software — under a quote-based, configuration-driven pricing model. Growth has been driven by a sustained M&A program (Tantti 2024, Metenova 2023, Avitide 2021 ~$150M, Polymem 2021, plus earlier Spectrum, C Technologies, ARTeSYN, TangenX, and Atoll deals) and strategic partnerships (notably Sartorius AG for integrated upstream solutions), supported by a $600M convertible senior notes offering in December 2023.

Short descriptiontext

Repligen is a publicly traded bioprocessing technology company that develops consumables, filtration, chromatography, and process analytics systems used by biopharmaceutical manufacturers, CDMOs, and advanced therapy developers to produce monoclonal antibodies, viral vectors, mRNA, pDNA, and ADCs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices20 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioprocessing equipment, tangential flow filtration, protein chromatography resins, single-use bioprocess, cell culture intensification
Industry1 code
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Bioprocessing Equipment and Consumables
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Capital Equipment Sales
TypeHardware Sales
Description

Sale of bioprocessing capital equipment including TFF systems (KrosFlo family), chromatography systems (KRM), XCell ATF systems, and real-time process management systems. Equipment ranges from bench-scale development tools to large-scale GMP production systems.

repligen.com
2Consumables
TypeHardware Sales
Description

Recurring revenue from single-use consumables including chromatography resins (AVIPure, HiPer, CaptivA), TFF cassettes (TangenX), hollow fiber filters (Spectrum), flow paths (ProConnex), and process analytics consumables.

repligen.com
3Services and Support
TypeProfessional Services
Description

Professional services including installation, qualification (IQ/OQ), preventive maintenance, calibration, spare parts, and service plans (Essential, Protected, Complete). Also includes training and application support services.

repligen.com
4Software
TypeSubscription Recurring
Description

Software solutions including KF Comm 2, KlariFi, and VPT software for process control, monitoring, and data management in bioprocessing operations.

repligen.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Enterprise/Bulk pricing
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Volume-based pricing for large-scale manufacturing customers and CDMOs. Custom configurations for GMP production environments.

repligen.com
2Standard product pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Process development and pilot-scale products available through direct sales and e-commerce store with quote-based pricing.

repligen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1XCell ATF
Description

Single-use perfusion system with controller and hollow fiber module for intensified cell culture processes

repligen.com
+9 more records
Core offering1 text field

Repligen designs, manufactures, and sells bioprocessing technologies used in the manufacture of biological drugs. Its offering spans upstream cell-culture intensification (XCell ATF), single-use and process filtration (KrosFlo TFF, TangenX cassettes, Spectrum hollow fibers), downstream purification (OPUS pre-packed chromatography columns, KRM chromatography systems, AVIPure and other resins, ProConnex flow paths), and process analytics (PATsmart variable-pathlength UV instruments). Products are sold to biopharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs) for use in clinical and commercial biologics production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 14% organic revenue growth achieved in FY2025
+3 more records
Product overview1 text field

Repligen offers an integrated bioprocessing technology platform for biopharmaceutical manufacturing, spanning both upstream and downstream operations. The portfolio centers on XCell ATF perfusion systems, KrosFlo TFF systems (tangential flow filtration), KRM chromatography systems, and OPUS pre-packed chromatography columns as core platforms. Supporting these are PATsmart process analytics products (FlowVPX, SoloVPE, REBEL XT, MAVEN, MAVERICK, ZipChip) for real-time monitoring, ProConnex flow paths for single-use fluid management, and a comprehensive range of consumables including AVIPure and HiPer affinity/ion exchange resins, cell culture supplements (LONG R3 IGF-I, LONG EGF), ligands (rSPA, Protein A), ELISA kits, and SpectraPor dialysis products. The company serves monoclonal antibodies, viral vectors, mRNA, pDNA, ADC, and cell therapy manufacturing workflows, providing both hardware systems and consumables that scale from process development through GMP commercial manufacturing.

Product and service1 record
1XCell ATF (Alternating Tangential Flow) Systems
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

In August 2023, Germany-based Sartorius AG partnered with US-based Repligen Corporation to introduce an integrated upstream bioprocessing system combining BIOSTAT STR and XCell ATF technologies for biopharmaceutical manufacturing. The partnership enables end-to-end process solutions for customers seeking integrated perfusion bioreactor and cell retention solutions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global bioprocessing leader within Danaher providing ÄKTA chromatography systems, MabSelect resins, Xuri cell expansion, and filtration solutions. Competes directly with Repligen across TFF, chromatography columns, and process analytics across all major biopharma markets.

TypeEmerging player
Description

Analytical instruments specialist providing chromatography and mass spectrometry systems used in bioprocess analytics and quality control. Comparable to Repligen's PATsmart analytics franchise in bioprocess analytical instrumentation.

TypeEmerging player
Description

Life sciences company with a growing bioprocessing presence through ProteinSimple (analytical instruments) and cell culture supplements. Provides complementary process monitoring and analytical solutions adjacent to Repligen's PAT portfolio.

TypeBroad incumbent
Description

Global supplier of laboratory products, bioprocessing materials, and single-use consumables through its bioproduction segment. Competes with Repligen in bioprocess fluids, buffers, and single-use fluid management solutions.

TypeBroad incumbent
Description

Diversified life sciences giant competing through its Life Sciences Solutions segment (Gibco cell culture, Patheon CDMO, Poros chromatography resins). Competes with Repligen across chromatography, bioprocessing consumables, and PAT instruments as part of a broader portfolio.

6Merck KGaA (Life Science / MilliporeSigma)
TypeDirect peer
Description

Major bioprocessing player offering Mobius single-use solutions, filtration, chromatography, and cell culture media through MilliporeSigma. Competes with Repligen in TFF cassettes, chromatography resins, and bioprocess consumables.

7Asahi Kasei Medical
TypeDirect peer
Description

Japanese bioprocessing company offering Planova virus filters, bioprocess equipment, and hollow fiber membranes. Competes with Repligen in filtration and selected bioprocessing product categories, particularly in Asia-Pacific.

TypeDirect peer
Description

German bioprocessing leader offering bioreactors (BIOSTAT STR), filtration, and cell culture media. Direct competitor in upstream bioprocessing and Repligen's strategic partner for integrated BIOSTAT STR + XCell ATF systems — competing in perfusion and single-use bioreactors globally.

TypeDirect peer
Description

German bioprocessing and lab equipment provider offering bioreactors (BioFlo), cell culture, and consumables. Competes with Repligen in selected bioprocessing equipment and consumables categories globally.

10Pall Corporation (Danaher)
TypeDirect peer
Description

Filtration and bioprocessing specialist providing TFF cassettes, hollow fiber filters, and chromatography systems under Danaher. Direct competitor in tangential flow filtration and single-use fluid management solutions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A11 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Repligen

Bioprocessing Equipment and Consumablesrepligen.com

Repligen is a publicly traded bioprocessing technology company that develops consumables, filtration, chromatography, and process analytics systems used by biopharmaceutical manufacturers, CDMOs, and advanced therapy developers to produce monoclonal antibodies, viral vectors, mRNA, pDNA, and ADCs.

What Repligen does

Repligen Corporation (NASDAQ: RGEN) is a publicly traded bioprocessing technology company founded in 1981 and headquartered in Waltham, Massachusetts. It develops and manufactures consumables, equipment, and integrated systems used by biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and advanced therapy developers for the production of biological drugs including monoclonal antibodies, viral vectors, mRNA, pDNA, and antibody-drug conjugates.

The product portfolio spans four integrated franchises: upstream filtration (XCell ATF perfusion systems for cell retention and process intensification), downstream processing (KrosFlo TFF systems, TangenX cassettes, Spectrum hollow fiber filters), chromatography (KRM systems, OPUS pre-packed columns spanning 1.2cm to 80cm diameters, AVIPure and HiPer affinity/ion exchange resins), and process analytics (PATsmart family including FlowVPX, SoloVPE, REBEL XT, and ZipChip instruments built on proprietary Variable Pathlength Spectroscopy). Supporting these are fluid management solutions (ProConnex flow paths, Metenova magnetic mixing), cell culture supplements (LONG R3 IGF-I, LONG EGF), ligands (rSPA, Protein A, NGL-Impact A), and the Real-time Process Management (RPM) platform that ties FlowVPX analytics directly into KrosFlo TFF for closed-loop concentration control. Manufacturing spans 13+ ISO-certified facilities across the US, Netherlands, Germany, Sweden, Ireland, Estonia, and Taiwan.

Repligen operates a hybrid B2B go-to-market combining direct enterprise field sales supported by field application specialists, an e-commerce storefront for standard products, and a global distributor network. Revenue is generated through capital equipment sales (TFF, chromatography, perfusion systems), recurring consumables (resins, cassettes, filters, flow paths), professional services (installation, qualification, maintenance, training), and software — under a quote-based, configuration-driven pricing model. Growth has been driven by a sustained M&A program (Tantti 2024, Metenova 2023, Avitide 2021 ~$150M, Polymem 2021, plus earlier Spectrum, C Technologies, ARTeSYN, TangenX, and Atoll deals) and strategic partnerships (notably Sartorius AG for integrated upstream solutions), supported by a $600M convertible senior notes offering in December 2023.

Repligen firmographics

Firmographics
Name
Repligen
Legal name
Repligen Corporation
Website
https://repligen.com
Company type
Public
Founded year
1981
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Repligen is a publicly traded bioprocessing technology company that develops consumables, filtration, chromatography, and process analytics systems used by biopharmaceutical manufacturers, CDMOs, and advanced therapy developers to produce monoclonal antibodies, viral vectors, mRNA, pDNA, and ADCs.
Ownership category
akta.pro rank

Repligen industry classification

Industry
Product category
Bioprocessing Equipment and Consumables
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Bioprocessing equipment
  • Tangential flow filtration
  • Protein chromatography resins
  • Single-use bioprocess
  • Cell culture intensification

Where Repligen is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices20 records

Markets served

Repligen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Capital Equipment Sales: Sale of bioprocessing capital equipment including TFF systems (KrosFlo family), chromatography systems (KRM), XCell ATF systems, and real-time process management systems. Equipment ranges from bench-scale development tools to large-scale GMP production systems.
  2. Consumables: Recurring revenue from single-use consumables including chromatography resins (AVIPure, HiPer, CaptivA), TFF cassettes (TangenX), hollow fiber filters (Spectrum), flow paths (ProConnex), and process analytics consumables.
  3. Services and Support: Professional services including installation, qualification (IQ/OQ), preventive maintenance, calibration, spare parts, and service plans (Essential, Protected, Complete). Also includes training and application support services.
  4. Software: Software solutions including KF Comm 2, KlariFi, and VPT software for process control, monitoring, and data management in bioprocessing operations.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractEnterprise/Bulk pricing
Unit PricingPay-as-you-goStandard product pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels10 records

Repligen product offering

Product offering

Core offering

Repligen designs, manufactures, and sells bioprocessing technologies used in the manufacture of biological drugs. Its offering spans upstream cell-culture intensification (XCell ATF), single-use and process filtration (KrosFlo TFF, TangenX cassettes, Spectrum hollow fibers), downstream purification (OPUS pre-packed chromatography columns, KRM chromatography systems, AVIPure and other resins, ProConnex flow paths), and process analytics (PATsmart variable-pathlength UV instruments). Products are sold to biopharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs) for use in clinical and commercial biologics production.

Product overview

Repligen offers an integrated bioprocessing technology platform for biopharmaceutical manufacturing, spanning both upstream and downstream operations. The portfolio centers on XCell ATF perfusion systems, KrosFlo TFF systems (tangential flow filtration), KRM chromatography systems, and OPUS pre-packed chromatography columns as core platforms. Supporting these are PATsmart process analytics products (FlowVPX, SoloVPE, REBEL XT, MAVEN, MAVERICK, ZipChip) for real-time monitoring, ProConnex flow paths for single-use fluid management, and a comprehensive range of consumables including AVIPure and HiPer affinity/ion exchange resins, cell culture supplements (LONG R3 IGF-I, LONG EGF), ligands (rSPA, Protein A), ELISA kits, and SpectraPor dialysis products. The company serves monoclonal antibodies, viral vectors, mRNA, pDNA, ADC, and cell therapy manufacturing workflows, providing both hardware systems and consumables that scale from process development through GMP commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • XCell ATF: Single-use perfusion system with controller and hollow fiber module for intensified cell culture processes
  • KrosFlo
  • OPUS
  • TangenX
  • Spectrum
  • PATsmart
  • ProConnex
  • AVIPure
  • KRM
  • Metenova

Products and services

  • XCell ATF (Alternating Tangential Flow) Systems

Quantifiable outcome

  • 14% organic revenue growth achieved in FY2025
  • +3 more outcomes

Companies that use Repligen

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Repligen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Repligen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sartorius AGcoreStrategic or Co-development Partner · 1 August 2023In August 2023, Germany-based Sartorius AG partnered with US-based Repligen Corporation to introduce an integrated upstream bioprocessing system combining BIOSTAT STR and XCell ATF technologies for biopharmaceutical manufacturing. The partnership enables end-to-end process solutions for customers seeking integrated perfusion bioreactor and cell retention solutions.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Repligen competitors and assessment

Company assessment

Direct peers

  • Cytiva (Danaher): Global bioprocessing leader within Danaher providing ÄKTA chromatography systems, MabSelect resins, Xuri cell expansion, and filtration solutions. Competes directly with Repligen across TFF, chromatography columns, and process analytics across all major biopharma markets.
  • Merck KGaA (Life Science / MilliporeSigma): Major bioprocessing player offering Mobius single-use solutions, filtration, chromatography, and cell culture media through MilliporeSigma. Competes with Repligen in TFF cassettes, chromatography resins, and bioprocess consumables.
  • Asahi Kasei Medical: Japanese bioprocessing company offering Planova virus filters, bioprocess equipment, and hollow fiber membranes. Competes with Repligen in filtration and selected bioprocessing product categories, particularly in Asia-Pacific.
  • Sartorius AG: German bioprocessing leader offering bioreactors (BIOSTAT STR), filtration, and cell culture media. Direct competitor in upstream bioprocessing and Repligen's strategic partner for integrated BIOSTAT STR + XCell ATF systems — competing in perfusion and single-use bioreactors globally.
  • Eppendorf: German bioprocessing and lab equipment provider offering bioreactors (BioFlo), cell culture, and consumables. Competes with Repligen in selected bioprocessing equipment and consumables categories globally.
  • Pall Corporation (Danaher): Filtration and bioprocessing specialist providing TFF cassettes, hollow fiber filters, and chromatography systems under Danaher. Direct competitor in tangential flow filtration and single-use fluid management solutions.

Emerging players

  • Waters Corporation: Analytical instruments specialist providing chromatography and mass spectrometry systems used in bioprocess analytics and quality control. Comparable to Repligen's PATsmart analytics franchise in bioprocess analytical instrumentation.
  • Bio-Techne: Life sciences company with a growing bioprocessing presence through ProteinSimple (analytical instruments) and cell culture supplements. Provides complementary process monitoring and analytical solutions adjacent to Repligen's PAT portfolio.

Broad incumbents

  • Avantor: Global supplier of laboratory products, bioprocessing materials, and single-use consumables through its bioproduction segment. Competes with Repligen in bioprocess fluids, buffers, and single-use fluid management solutions.
  • Thermo Fisher Scientific: Diversified life sciences giant competing through its Life Sciences Solutions segment (Gibco cell culture, Patheon CDMO, Poros chromatography resins). Competes with Repligen across chromatography, bioprocessing consumables, and PAT instruments as part of a broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Repligen social profiles

Digital presence

Repligen compliance and trust

Trust signal

Compliance3 records

Repligen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Repligen leadership team

Management profile

Number of profiles

Profiles6 records

Repligen subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Repligen funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Repligen M&A and investment

M&A and investment

M&A11 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Repligen

What does Repligen do?

Repligen designs, manufactures, and sells bioprocessing technologies used in the manufacture of biological drugs. Its offering spans upstream cell-culture intensification (XCell ATF), single-use and process filtration (KrosFlo TFF, TangenX cassettes, Spectrum hollow fibers), downstream purification (OPUS pre-packed chromatography columns, KRM chromatography systems, AVIPure and other resins, ProConnex flow paths), and process analytics (PATsmart variable-pathlength UV instruments). Products are sold to biopharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs) for use in clinical and commercial biologics production.

Is Repligen a public or private company?

Repligen is a public company. It is classified as public and is currently operating.

When was Repligen founded?

Repligen was founded in 1981. It employs 1,001 to 5,000 people.

Where is Repligen based?

Repligen is headquartered in Waltham, United States, in the North America region.

How does Repligen make money?

Four revenue lines are on record. Capital Equipment Sales are the primary driver. The others are consumables, services and Support and software.

Who are Repligen's main competitors?

Direct peers on record are Cytiva (Danaher), Merck KGaA (Life Science / MilliporeSigma), Asahi Kasei Medical, Sartorius AG, Eppendorf and Pall Corporation (Danaher). Emerging players are Waters Corporation and Bio-Techne. Broad incumbents are Avantor and Thermo Fisher Scientific.

Does Repligen have an API?

No public API is recorded for Repligen.

What industry is Repligen in?

Repligen's product category is Bioprocessing Equipment and Consumables. Its primary akta.pro industry code is HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewRGEN: Q3 orders and recovering modalities set up a stronger 2027 growth outlookRepligen Corporation's Q3 orders and recovering modalities support a potential 2027 capital expenditure rebound. BioLife synergies, protein growth, and new modalities underpin the outlook, with at least five points of market outgrowth targeted for 2027.Defense World3,054 Shares in Repligen Corporation $RGEN Bought by Ethic Inc.Ethic Inc. acquired a new stake in Repligen Corporation, buying 3,054 shares valued at approximately $587,000 in Q3. Analysts rate the stock a Moderate Buy with a consensus price target of $178.57, and Repligen reported Q3 EPS of $0.53, beating estimates.American Banking and Market NewsRepligen Corporation $RGEN Shares Newly Purchased by Ethic Inc.Ethic Inc. acquired a new stake in Repligen Corporation, purchasing 3,054 shares valued at about $587,000 in Q3. The company reported Q3 EPS of $0.53, beating estimates, and revenue rose 10.9% year-over-year. Analysts have a consensus price target of $178.57.MarketWatchStocks to Watch: Repligen, Hawaiian Electric, GeoVax LabsRepligen issued $1 billion in convertible senior notes due 2031, and its shares fell 20% to $138.99. Hawaiian Electric reported higher profit and 28% revenue growth, pushing its stock up 2.9% to $8.66. GeoVax Labs fired CEO David Dodd for refusing board directives, and its stock dropped 4.3% to 15 cents.MarketWatchRepligen Shares Fall on $1B Note IssuanceRepligen issued $1 billion in convertible senior notes, causing shares to fall 20% to $138.99 after-hours. The notes carry a 0.25% rate and mature Nov. 1, 2031, with about $541.4 million issued for existing notes and cash.TradingViewRepligen Issues $1 Billion of 0.25% Convertible Notes Due 2031Repligen issued $1 billion of 0.25% convertible senior notes due 2031 under a new indenture. About $541.4 million went to holders exchanging $456.8 million of 2028 notes, while $458.6 million was sold for cash, leaving $143.2 million of 2028 notes outstanding. The financing refinances existing debt and raises cash proceeds.Simply Wall StCan Repligen (RGEN) Justify Its Valuation After Revenue Growth And A Large Impairment?Repligen reported Q3 revenue growth of 10.9% year over year but a 65.9% drop in earnings per share, driven by a US$41.24 million intangible asset impairment. The company's share price fell 5.45% in one day and 10.69% over seven days, while a valuation narrative suggests a fair value of $199.70.American Banking and Market NewsRepligen Corporation $RGEN Stock Sold by Conestoga Capital Advisors LLCConestoga Capital Advisors cut its Repligen stake by 28.6% in Q3, selling 280,357 shares. Repligen reported Q3 EPS of $0.53, beating estimates, with revenue up 10.9% year-over-year. Analysts have a consensus price target of $178.57.American Banking and Market News9,167 Shares of Repligen Corporation $RGEN Bought by Factory Mutual Insurance Co.Factory Mutual Insurance Co. bought a new stake in Repligen Corporation during Q3, purchasing 9,167 shares valued at about $1.76 million. Analysts have an average "Moderate Buy" rating with a consensus target price of $178.57, and the company reported Q3 EPS of $0.53, beating estimates.